title: Fludarabine therapy in chronic lymphocytic leukemia-associated severe nephrotic syndrome.
authors.forename: M M
authors.initials: MM
authors.lastname: Abdel-Raheem
authors.forename: M G
authors.initials: MG
authors.lastname: Jamil
authors.forename: A
authors.initials: A
authors.lastname: Potti
authors.forename: G G
authors.initials: GG
authors.lastname: Gross
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology; D012074:Remission Induction; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine